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Herpesviruses are ancient pathogens that infect all vertebrates. The most conserved component
of their entry machinery is glycoprotein B (gB), yet how gB functions is unclear. A striking feature
of the murid herpesvirus 4 (MuHV-4) gB is its resistance to neutralization. Here, we show by
direct visualization of infected cells that the MuHV-4 gB changes its conformation between
extracellular virions and those in late endosomes, where capsids are released. Specifically,
epitopes on its N-terminal cell-binding domain become inaccessible, whilst non-N-terminal
epitopes are revealed, consistent with structural changes reported for the vesicular stomatitis
virus glycoprotein G. Inhibitors of endosomal acidification blocked the gB conformation switch.
They also blocked capsid release and the establishment of infection, implying that the gB switch is
a key step in entry. Neutralizing antibodies could only partially inhibit the switch. Their need to
engage a less vulnerable, upstream form of gB, because its fusion form is revealed only in
endosomes, helps to explain why gB-directed MuHV-4 neutralization is so difficult.
INTRODUCTION
Herpesviruses are ubiquitous, persistent parasites whose
behaviour impinges significantly on vertebrate biology.
They characteristically use immune evasion to spread from
primed, immunocompetent hosts, and viral CD8
+ T-cell-
evasion mechanisms are well known (Yewdell & Hill,
2002). Much less is known of how herpesviruses evade pre-
formed antibody. We are using murid herpesvirus 4
(MuHV-4) to define molecular mechanisms behind the
epidemiologically evident resistance of herpesviruses to
neutralization (Xu et al., 1996). One important factor may
be antibody-coated virions exploiting host Fc receptors for
uptake when normal cell binding is blocked (Rosa et al.,
2007). This critically requires that viral membrane fusion
remains intact. Thus, a key question is how membrane
fusion avoids inhibition by antibody.
One possibility is that the fusion machinery remains hidden
on cell-free virions, much as conformation changes in the
human immunodeficiency virus gp120 restrict antibody
access until after cell binding (Chen et al., 2005). Herpes
simplex virus (HSV) entry is initiated by conformation
changes in glycoprotein D (gD) (Fusco et al., 2005;
Krummenacher et al., 2005), an alphaherpesvirus-specific
addition to the core fusion complex (Spear & Longnecker,
2003). The inhibitory effects of gp150 on MuHV-4 infection
of cells with low glycosaminoglycan (GAG) expression (de
Lima et al., 2004) and of gp350 on Epstein–Barr virus
infection of epithelial cells (Shannon-Lowe et al., 2006)
suggest that gammaherpesvirus entry may be triggered
similarly.However,gD,gp150or gp350 could hardly protect
the whole, multi-protein entry machinery. Their engage-
ment is probably just the first of several conformation
changes in virion glycoproteins that cumulate in membrane
fusion. Understanding how each glycoprotein changes in the
context of infection should tell us the limits imposed on
antibody-mediated neutralization.
We have focused on gB, the most conserved component of
herpesvirus membrane fusion (Turner et al., 1998). The
HSV gB structure (Heldwein et al., 2006) provides a
template for understanding these proteins as a whole.
Comparison with vesicular stomatitis virus glycoprotein G
(VSV-G) (Roche et al., 2006, 2007) suggests that herpes-
virus gBs might adopt distinct conformations during entry,
with the solved structure a downstream form.
Although gB is exposed on MuHV-4 virions (Lopes et al.,
2004), it presents a very difficult neutralization target
(Gillet et al., 2006). As with other herpesviruses (Ohlin
et al., 1993; Holloway et al., 1998; Akula et al., 2002;
Okazaki et al., 2006), the gB N terminus is a neutralization
target for MuHV-4 (Gillet et al., 2006). However, this
neutralization requires IgM monoclonal antibodies
(mAbs), which are rare in MuHV-4 carriers, and even
then remains incomplete. In order to understand how gB is
exposed to antibody, we used conformation-specific mAbs
to track its antigenicity during viral entry. By keeping to
the context of infectious virions, we preserved important
interactions between gB and other virion glycoproteins
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of a dramatic gB conformation shift that sheds new light on
how herpesviruses resist neutralization.
METHODS
Cells and viruses. BHK-21 fibroblasts, NMuMG epithelial cells,
NIH-3T3 fibroblasts, 293T cells, NS0 myeloma cells, MCCD polarized
murine epithelial cells, COS-7 cells, CHO-K1 cells (ATCC) and the
gB–glycosylphosphatidylinositol (GPI)-expressing derivative CHO-gB
(Lopes et al., 2004) were all grown in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 2 mM glutamine, 100 U
penicillin ml
21, 100 mg streptomycin ml
21 and 10% fetal calf serum
(PAA Laboratories). 293T cells were transfected with the GPI-linked
gB extracellular domain or domains derived from it (Gillet et al.,
2006) by using FuGENE 6 (Roche Diagnostics). All viruses were
derived from a cloned MuHV-4 bacterial artificial chromosome
(Adler et al., 2000). Virions were harvested from infected BHK-21 cell
supernatants by ultracentrifugation; infected-cell debris was removed
by low-speed centrifugation (May et al., 2005a). Of note, rigorous
removal of infected-cell debris was critical for clean immunofluor-
escence data. In some experiments, we purified virions further on
Ficoll gradients, but this made no difference to the data obtained.
mAbs. mAbs were derived from MuHV-4-infected BALB/c mice at
least 3 months post-infection by fusion of spleen cells with NS0 cells
(Ko ¨hler & Milstein, 1975). The mAbs used in this study are listed in
Table 1. All glycoprotein-specific mAbs were selected first by their
capacity to recognize virus-infected cells; each was then typed for its
target glycoprotein (Gillet et al., 2007a).
Neutralization assays. Viruses were pre-incubated (2 h at 37 uC)
with dilutions of immune sera or mAbs, and then added to BHK-21
or NMuMG cell monolayers. After a further 2 h, the monolayers were
overlaid with 0.3% carboxymethylcellulose. The monolayers were
fixed in 4% formaldehyde after 4 days for BHK-21 cells and after
6 days for NMuMG cells. The fixed cells were stained with 0.1%
toluidine blue and plaques were counted with a plate microscope
(Olympus).
Immunofluorescence. Cells were plated onto coverslips overnight,
then exposed to MuHV-4 virions (3 p.f.u. per cell). After three washes
in PBS to remove unbound virions, the cells were fixed in PBS with
4% paraformaldehyde (30 min) and permeabilized with 0.1% Triton
X-100 (15 min). Viral glycoproteins were detected with murine mAbs
plus either Alexa 488- or Alexa 568-conjugated goat anti-mouse IgG
(Invitrogen) or a combination of Alexa 488- or Alexa 633-conjugated
goat anti-mouse IgG1 and Alexa 568-conjugated goat anti-mouse
IgG2a. None of the MuHV-4 mAbs used for immunofluorescence
gave detectable staining of uninfected cells. Lysosome-associated
membrane protein 1 (LAMP-1) was detected with the rat mAb 104B
(BD Pharmingen) and Alexa 488- or Alexa 568-conjugated goat anti-
rat IgG (Invitrogen). Nuclei were counterstained with DAPI (4,6-
diamidino-2-phenylindole). Fluorescence was visualized with a Leica
confocal microscope imaging single 1 mm sections, except for Figs 2
and 3, when we used an Olympus IX70 microscope plus a Retiga
2000R camera line (QImaging).
Flow cytometry. Cells exposed to enhanced green fluorescent protein
(eGFP)
+ viruses were washed twice in PBS and analysed directly for
green-channel fluorescence. For surface staining, cells were incubated
(1 h at 4 uC) with MuHV-4 glycoprotein-specific mAbs followed by
fluorescein-conjugated rabbit anti-mouse IgG pAb (Dako
Cytomation). All cells were washed twice in PBS after treatment
with each antibody and analysed on a FACScalibur (BD Biosciences).
RESULTS
Recombinant and infected-cell gB express the
same epitopes, but in different proportions
mAbs that recognize both infected cells and recombinant gB
define its accessible surface (Lopes et al., 2004). The relative
efficiencies withwhichsuchmAbsrecognized each form ofgB
Table 1. mAbs used in this study
mAb Target* Isotype EpitopeD Reference
BN-1A7 gB-N IgG2a Conformational This paper
BN-2B11 gB-N IgG2a Conformational This paper
10A4 gB-N IgG2a Conformational This paper
MG-15F6 gB-N IgG2a Conformational This paper
BH-6B5 gB-N IgM Conformational This paper
MG-2C10 gB-N IgM Linear Gillet et al. (2006)
BN-6E1 gB-N IgM Linear This paper
BH-8F4 gB-N IgM Linear This paper
MG-1A12 gB IgG2a Conformational Gillet et al. (2006)
MG-4A1 gB IgG1 Conformational This paper
MG-4D11 gB-C IgG2a Linear Gillet et al. (2006)
T4H7 gp70 IgM Conformational This paper
T6G10 gp70 IgM Conformational This paper
BN-3A4 gp150 IgG1 Linear This paper
3F7 gN IgG2a Linear May et al. (2005b)
MG-12B8 ORF65 (capsid) IgG2a Linear Gillet et al. (2006)
*gB-N, The portion of gB N-terminal to its furin-cleavage site was sufficient for mAb recognition; gB-C, the
portion C-terminal to the furin-cleavage site.
DBased on the recognition or not of denatured protein in immunoblots.
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recognizes a linear epitope near the MuHV-4 gB N terminus
(Gillet et al., 2006), showed less difference between native and
recombinant gB than did MG-4D11, which recognizes an
epitope C-terminal to the gB furin-cleavage site (gB-C). BN-
1A7 recognizes an epitope N-terminal to the gB furin-
cleavage site (gB-N) (Fig. 2) and was similar to MG-2C10.
MG-1A12, which requires both gB-N and gB-C for
recognition, was similar to MG-4D11. Thus, native and
recombinant gB were antigenically distinct. BHK-21 cells
infected with vaccinia virus expressing gB–GPI (Gillet et al.,
2007b) showed staining similar to that of CHO-gB cells (data
not shown). The BN-1A7 and MG-1A12 staining patterns
were each observed with at least eight different gB-specific
mAbs. All of those mapping to gB-N were similar to BN-1A7.
Virion gB changes its antigenicity during virus
entry
Infected cells may display antigens from entering and exiting
virions and non-virion glycoproteins. We analysed entering
virions specifically by binding them to uninfected cells.
MuHV-4 infects via endocytosis (Gill et al., 2006), so we first
bound the virions at 4 uC and then shifted the temperature to
37 uC to compare pre- and post-endocytosis (Fig. 1b). Single
cells are shown for optimal resolution. In Fig. 1, as in
subsequent figures, each cellshownis fully representative of at
least 75% of the total examined (n.100).
mAb MG-4D11 recognized gB both before and after
endocytosis. In contrast, BN-1A7 recognized gB strongly at
the cell surface and poorly after endocytosis, whilst MG-
1A12 recognized endocytosed gB only. Virion gB therefore
changed its antigenicity during entry into NMuMG cells.
Other cell lines showed the same change (Fig. 3). It
occurred after endocytosis, as BN-1A7 staining still co-
localized with an invariant epitope defined by mAb MG-
4A1 in peripheral endosomes, whereas MG-1A12 staining
co-localized with MG-4A1 only in more central endosomes
(Fig. 1c; see also Fig. 4b). This difference in co-localization
made it clear that BN-1A7 and MG-1A12 recognize gB at
different stages of entry. The complete shift in virion gB





+ argued that these forms are mutually exclusive.
Thus, gB-transfected and MuHV-4-infected cells, which
were each recognized by both mAbs, must each express
both forms, but in different proportions.
The MuHV-4 gB-N corresponds to domains I and II of the
HSV gB, which hang down on extended peptide loops in its
published structure (Heldwein et al., 2006). The domain II
equivalent of the structurally analogous VSV-G (its domain
III) occupies a comparable position in its post-fusion
conformation (Roche et al., 2006), but is more exposed in
the pre-fusion form, where it contributes much of the likely
receptor-binding site (Roche et al., 2007). A similar pre-
fusion exposure of gB domain II would be consistent with the
cellbinding of solublegB-N (Gillet et al., 2007c) and with gB-
N-specific mAbs, such as BN-1A7, preferentially recognizing
pre-fusion gB (Fig. 1); the post-endocytic loss of BN-1A7
staining would reflect domain II moving to a more
dependent position in post-fusion gB. It therefore seemed
likely that gB has pre- and post-fusion conformations,
much like VSV-G (we keep to the convention of ‘post-
fusion’ being the fusion-competent form of a glycopro-
tein, although the VSV-G and gB crystal structures include
neither ligand nor lipid and so are not strictly post-
fusion). The main alternative explanation for one gB
conformational epitope disppearing at the same time as
another appears – an elaborate shift in an antigen-
masking protein from one site on gB to another – seems
very unlikely. The only MuHV-4 glycoproteins known to
associate with gB are gH/gL and gp150 (Gillet &
Stevenson, 2007a). Virions lacking gL, which display a
markedly different gH conformation from the wild type
(Gillet et al., 2007d), or lacking gp150 showed exactly the
same changes in gB antigenicity (data not shown).
The gB conformation change occurs close to
membrane fusion
How does the gB conformation change relate to membrane
fusion? mAb MG-12B8 defines an MuHV-4 capsid epitope
that is inaccessible on intact virions, but revealed once they
have uncoated (Gillet et al., 2006). The MG-12B8 epitope
appears when incoming virion glycoproteins reach the late
endosomes/lysosomes marked by LAMP-1 (Marsh et al.,
1987) (Fig. 4a). This coincides with the change in gB
antigenicity (Fig. 4b): MG-1A12 staining co-localized with
LAMP-1, whereas BN-1A7 staining was evident only in
peripheral, LAMP-1
2 endosomes. The gB conformation
change therefore occurs close in time and place to
membrane fusion. This implied that BN-1A7
+ gB engages
in binding, whilst MG-1A12
+ gB mediates fusion.
The gB conformation change is pH-dependent
The delay in MuHV-4 capsid release until virions reach
LAMP-1
+ endosomes (Fig. 4a) suggests that membrane
fusion requires a low pH. This was confirmed by inhibitors
of lysosomal acidification blocking both infection (Fig. 5a)
and capsid release (Fig. 5b). Virion glycoproteins (gN in
Fig. 5b) were still endocytosed and reached LAMP-1
+
endosomes, but the BN-1A7 gB epitope was preserved and
now co-localized with LAMP-1, whereas the MG-1A12
epitope failed to appear. Thus, the gB conformation change
was pH-dependent and again linked to membrane fusion.
NH4Cl also blocked the conformation change but, like
chlorpromazine, mainly blocked endocytosis (Fig. 6).
Exposing cell-bound virions to low pH triggered the gB
conformation change with only low efficiency (Fig. 5c).
Thus, exposure to a pH of 4 increased MG-1A12 gB
staining, but without much change in BN-1A7 staining.
The number of gB molecules changing was evidently much
lower than in normal infection (Fig. 1b). This argues that
ligand engagement or another aspect of the endosomal
L. Gillet, S. Colaco and P. G. Stevenson
1354 Journal of General Virology 89Fig. 1. gB changes conformation after endocytosis. (a) mAbs were compared by flow cytometry for their staining of uninfected
(UI, solid lines) or MuHV-4-infected (vir, short-dashed lines) BHK-21 cells, or CHO cells expressing a GPI-linked gB
extracellular domain (CHO-gB, long-dashed lines). Each mAb is representative of at least five examples, each tested in at least
three different experiments. (b) Virions were attached to NMuMG cells (2 h at 4 6C), washed three times with PBS, then either
fixed immediately (4 6C) or first incubated (2 h at 37 6C) to allow endocytosis. All cells were then permeabilized and stained for
gB (green). Nuclei were counterstained with DAPI (blue). Equivalent data were obtained in five repeat experiments. (c) Cells
were incubated with virions (2 h at 4 6C), with or without allowing subsequent endocytosis (2 h at 37 6C) as in (b), then fixed,
permeabilized and stained with the gB-specific mAbs BN-1A7 or MG-1A12 (both IgG2a, red), plus MG-4A1 (IgG1, green),
which recognizes an invariant epitope. Co-localization of isotype-specific secondary-antibody staining is yellow in the merged
image. The arrowhead in the MG-4A1/BN-1A7 merge shows co-localization outside more central MG-4A1-only staining. The
arrowhead in the MG-4A1/MG-1A12 merge shows peripheral MG-4A1-only staining, with more central co-localization.
Equivalent data were obtained in three repeat experiments.
MuHV-4 gB
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necessarily sufficient, low pH was clearly necessary.
Neutralization is limited to IgMs that recognize
gB-N
MG-2C10 is representative of several IgM mAbs that
recognize the gB N terminus and block infection at a post-
binding step (Gillet et al., 2006). In three further fusions,
we identified three more gB-specific neutralizing mAbs (in
addition to re-isolating MG-2C10-like mAbs) (Fig. 7a).
Again, all were IgMs. None of 85 gB-specific IgGs identified
in the same fusions gave significant neutralization; Fig. 7(a)
shows three examples. mAb reduction confirmed that a
pentameric structure was crucial for neutralization
(Fig. 7b). Neutralization was not a general property of
IgMs, as gp70-specific IgMs failed to neutralize (Fig. 7a).
Although most gB-specific mAbs were like MG-1A12 and
required all of gB for recognition, the gB-specific
neutralizing IgMs all mapped to gB-N (Fig. 7c). The new
IgMs recognized a different epitope than MG-2C10. Thus,
they reduced BN-1A7 binding much more than MG-2C10
did and had no effect on MG-15F6 binding, whereas MG-
2C10 inhibited MG-15F6 markedly (Fig. 7d) (based on
transfected gB truncation mutants, MG-15F6 recognition
requires residues 13–30 after the predicted gB signal
sequence cleavage, but not residues 2–13; MG-2C10
requires residues 2–6). The failure of gB-N-specific IgGs
such as BN-1A7 and MG-15F6 to neutralize, even though
their recognition sites overlapped with those of neutral-
izing IgMs, emphasized further that neutralization requires
an IgM isotype. Indeed, the more abundant gB-N-specific
IgGs in immune sera could conceivably outcompete gB-N-
specific IgMs to impair neutralization.
The gB conformation change is difficult for
antibodies to block
As with MG-2C10 (Gillet et al., 2006), BN-6E1, BH-6B5
and BH-8F4 blocked neither cell binding nor virion
endocytosis. Fig. 7(e) shows data for BH-6B5; the other
mAbs were equivalent. They partly inhibited the gB
conformation switch – BH-6B5 was the most effective,
Fig. 2. Localization of mAb epitopes on gB. In order to map mAb recognition, 293T cells were transfected with the full-length
gB extracellular domain fused to a GPI membrane anchor (gB), or with GPI-linked fragments of this domain either N-terminal
(gB-N) or C-terminal (gB-C) to its furin-cleavage site (Lopes et al., 2004). For gB-C expression, the native gB signal sequence
was retained as described previously (Gillet et al., 2006). Forty-eight hours after transfection, each population was fixed,
permeabilized and stained with gB-specific mAbs as indicated. mAb MG-2C10 gives high background intracellular staining; we
have therefore shown MG-15F6 for comparison, an IgG whose recognition site maps very close to that of MG-2C10 at the gB
N terminus (see also Fig. 7c). The neutralizing mAb BH-6B5 is also shown for comparison.
Fig. 3. Different cell lines show the same gB conformation change. Wild-type MuHV-4 virions were bound to cells (2 h at
4 6C). Unbound virions were then removed by washing with PBS and the cells were either fixed immediately (4 6C) or after a
further incubation (2 h at 37 6C) to allow endocytosis. All cells were then permeabilized with 0.1% Triton X-100 and stained for
MuHV-4 virion components as shown (green). Nuclei were counterstained with DAPI (blue). The MG-12B8 capsid epitope only
becomes accessible after virion uncoating (Gillet et al., 2006). The gN epitope is always accessible. In each cell line, gB
switched from BN-1A7
+ before endocytosis to MG-1A12
+ after endocytosis.
L. Gillet, S. Colaco and P. G. Stevenson
1356 Journal of General Virology 89MuHV-4 gB
http://vir.sgmjournals.org 1357retaining some BN-1A7
+ gB. However, unlike bafilomycin
or concanamycin A (Fig. 5b), they failed to block it
completely – Fig. 7(e) shows that MG-1A12
+ gB still
appeared. Thus, once virions get to late endosomes, the gB
conformation switch seems to be hard for antibodies to block.
As gB-N incorporates the putative gB fusion loops (Heldwein
et al., 2006), the gB-N-specific IgMs seemed more likely to
neutralize by hindering fusion sterically. This would explain
w h yt h e ymu s tb eI g M s ,a sth emu c hla r g e rs i z eo fI g M swo u l d
vastly increase their scope for steric hindrance.
Fig. 4. Glycoprotein conformation changes coincide with capsid release. (a) Virions were incubated with NMuMG cells (2 h at
4 6C), unbound virions were removed by washing three times with PBS and the cells were incubated at 37 6C for the time
indicated before fixing with paraformaldehyde, permeabilizing with Triton X-100 and staining for the ORF65 capsid component
with MG-12B8 [Alexa 568 (shown as green), with DAPI nuclear counterstaining in blue]. The cells were also stained for LAMP-1
(Alexa 488, green) and for gp150 with mAb BN-3A4 (Alexa 633, red). LAMP-1/gp150 co-localization appears yellow. Equivalent
resultswere obtained in four further experiments.(b) NMuMG cells were exposedto virions (2 h at4 6C), then washed three times
with PBS andeither fixed immediately or first incubated for2 h at 37 6C.All cells were then permeabilized andstainedforLAMP-1
(red) and for gB with mAbs BN-1A7 or MG-1A12 (green). Co-localization appears yellow. The arrowhead indicates residual BN-
1A7 staining confined to LAMP-1
” endosomes. Equivalent data were obtained in two further experiments.
L. Gillet, S. Colaco and P. G. Stevenson
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The MuHV-4 gB is a major component of virions (Lopes
et al., 2004). We have shown here that gB changes its
antigenicity during viral entry, consistent with a shift
between cell-binding and pro-fusion conformations. The
gB N-terminal domains, which participate in cell binding
(Gillet et al., 2007c), were more accessible on pre-fusion
gB. Their reduced accessibility after endocytosis was
consistent with the conformation change described for
VSV-G, with the solved gB structure (Heldwein et al.,
2006) being its ‘post-fusion’ form. The gB conformation
switch probably precedes actual fusion, as GPI-linked gB
readily adopted the ‘post-fusion’ form.
Low pH was important for the gB conformation switch.
This may explain why the MuHV-4 gB is a poor
neutralization target (Gillet et al., 2006). A requirement
for low pH would also explain why MuHV-4, like Kaposi’s
sarcoma-associated herpesvirus (KSHV) (Akula et al.,
Fig. 5. The gB conformation change is pH-dependent. (a) NMuMG cells were left untreated or cultured with bafilomycin or
concanamycin A as shown, and exposed to MuHV-4 expressing eGFP under the control of a cytomegalovirus IE-1 promoter.
Eighteen hours later, the proportion of eGFP
+ cells was quantified by flow cytometry. Equivalent data were obtained in two
further experiments. The same drug concentrations had no effect on infection by HSV (data not shown). (b) MuHV-4 virions
were bound to the cells (2 h at 4 6C) in the presence or absence of drugs as shown. The cells were then washed in PBS,
incubated with or without 100 nM bafilomycin or 100 nM concanamycin A for a further 2 h at 37 6C, then fixed, permeabilized
and stained for viral proteins. Equivalent data were obtained in two further experiments. (c) Virions were bound to NMuMG cells
(2 h at 4 6C), then exposed to different pH buffers (15 min at 37 6C), fixed, permeabilized and stained for virion glycoproteins
as shown. Equivalent data were obtained in two further experiments.
MuHV-4 gB
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membrane fusion is possible with transfected KSHV
glycoproteins (Pertel, 2002), and transfected MuHV-4 gB
could adopt its pro-fusion form (Fig. 1a). However, this is
a very different setting from infection. In the absence of
other virion glycoproteins, transfected gB may switch its
Fig. 6. Blocking endocytosis also blocks the gB conformation change. NMuMG cells were treated with NH4Cl or
chlorpromazine as shown and exposed to wild-type MuHV-68 virions (4 6C for 2 h, then washed three times in PBS, then
37 6C for 2 h). The cells were then fixed, permeabilized and stained for MuHV-68 virion components as shown (green). Nuclei
were counterstained with DAPI (blue). Representative cells are shown. Both drug treatments inhibited the shift in gB from BN-
1A7
+ to MG-1A12
+. Although NH4Cl is classically an inhibitor of endosomal acidification, it evidently acted here mainly by
blocking virion endocytosis.
Fig. 7. Neutralizing mAbs struggle to block the gB conformation change. (a) MuHV-4 virions were incubated with antibody
dilutions (2 h at 4 6C), then plaque-assayed on BHK-21 cells. Gp70 is the complement control protein encoded by ORF4. The
horizontal dashed line shows plaque numbers with virus alone. Equivalent data were obtained in three repeat experiments. (b)
The pentameric neutralizing IgMs were reduced to monomers with 10 mM dithiothreitol (DTT; 15 min at 4 6C), then tested for
plaque reduction on BHK-21 cells as before. Nil, ±DTT without antibody. Equivalent data were obtained in one repeat
experiment. All reduced IgMs still stained virus-infected cells by flow cytometry (data not shown). (c) 293T cells were
transfected with empty vector (solid lines), gB–GPI (short dashes) or gB-N–GPI (long dashes), then trypsinized 48 h later and
analysed for mAb recognition by flow cytometry. Control, secondary antibody only. All of the mAbs recognized gB–GPI. All of
the neutralizing mAbs (MG-2C10, BN-6E1, BH-8F4 and BH-6B5) recognized gB-N. BN-1A7 is a gB-N-specific control; MG-
4D11 is a gB-C-specific control. (d) MuHV-4-infected BHK-21 cells (2 p.f.u. per cell, 18 h) were incubated or not (nil) with gB-
specific IgMs (30 mgm l
”1,1ha t46C), then stained with gB-specific IgG2a mAbs (2 mgm l
”1). Control, secondary antibody
only. Thirty thousand cells per sample were then analysed by flow cytometry. The reductions in BN-1A7 staining by BN-6E1,
BH-6B5 and BH-8F4 were highly significant (P,0.0001 by Student’s t-test), as was the reduction in MG-15F6 staining by
MG-2C10 (P,0.0001). (e) MuHV-4 virions were pre-incubated or not with mAb BH-6B5, then added to NMuMG cells (2 h at
4 6C). The cells were then washed three times with PBS and incubated further (2 h at 37 6C) to allow endocytosis. The cells
were then fixed, permeabilized and stained with IgG2a mAbs plus an IgG2a-specific secondary antibody as shown. Similar
results were obtained in two repeat experiments and with the other neutralizing IgMs.
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the acidic environment of the trans-Golgi network
(Demaurex et al., 1998).
Although the cell-binding gB N-terminal domains are
accessible on MuHV-4 virions, these virions readily escape
from infected cells, suggesting that the binding site itself is
hidden. Moreover, gB-N–Fc binds to a non-GAG ligand,
but MuHV-4 cell binding is highly GAG-dependent
(Gillet et al., 2007c). gp150 regulates MuHV-4 binding
to a non-GAG cellular ligand (de Lima et al., 2004; Gillet
et al., 2007c), as gp150 knockouts are much less GAG-
dependent than the wild type (also, virions lacking gp150
do have a problem escaping from infected cells). The
obvious explanation would be that gp150 covers the gB-N
binding epitope until displaced by GAGs. Thus, gB has 2-
fold protection: masking by gp150 and a post-endocytic
conformation change. This protection allows efficient
virion release and hides gB from antibody.
Many mechanisms of virion neutralization have been
described (Klasse & Sattentau, 2002). By far the most
MuHV-4 gB
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to receptor binding (Knossow & Skehel, 2006). However,
the capacity of herpesviruses such as MuHV-4 to escape
from endosomes and infect Fc receptor-positive cells
productively (Rosa et al., 2007) forces neutralization to
act at post-binding steps, such as membrane fusion. Such
neutralization must cope with the dramatic conformation
changes characteristic of viral fusion proteins (Knossow &
Skehel, 2006). If antibody can bind only to the upstream
form of a glycoprotein, because its switch is secluded,
neutralization will be limited to steric hindrance – binding
common epitopes close to the fusion loops if such exist
– or to blocking the switch itself. Blocking the gB
conformation switch was evidently hard, presumably
because the pre-fusion conformation becomes highly
unstable in late endosomes. Also, steric hindrance seems
to require an IgM isotype, which is rare in steady-state B-
cell responses. The gB conformation change therefore helps
MuHV-4 to evade neutralization.
A post-endocytic gB conformation switch readily explains
why gB-directed MuHV-4 neutralization is more difficult
than for HSV (Bender et al., 2007) or human cytomegalo-
virus (Speckner et al., 1999). In the typical setting of
neutralization assays, HSV and cytomegalovirus fuse at the
plasma membrane (Compton et al., 1992; Browne et al.,
2001); conformation-switched gB is therefore accessible.
Neutralizing mAbs have accordingly been mapped to
prominent positions on post-fusion gB (Speckner et al.,
1999; Heldwein et al., 2006; Bender et al., 2007). In
contrast, mAbs specific for post-fusion MuHV-4 gB, such
as MG-1A12, never neutralized. HSV and cytomegalovirus
can also infect via endocytosis (Clement et al., 2006;
Ryckman et al., 2006) and this route may be harder for gB-
specific mAbs to block. However, a more important
consideration is where neutralization might act in the viral
life cycle. Herpesviruses mostly spread within their hosts
via cell–cell contacts (Peeters et al., 1993; Dingwell et al.,
1994). These probably exclude antibody (Roth & Compans,
1980). Thus, antibody reduces the intra-host lytic spread of
HSV, mainly by Fc receptor-dependent effector functions
(Balachandran et al., 1982; Rector et al., 1982; Kohl et al.,
1986); Fc inhibition, in turn, increases intra-host spread
(Nagashunmugam et al., 1998). Neutralization is more
relevant to cell-free virions, whose key role is inter-host
spread. Virions are exposed to antibody when they exit an
immune host. However, once they reach a new, naive host,
the only antibody capable of blocking infection is that
already attached. Epitopes revealed by conformation
changes are therefore safe: as with endocytic uptake, they
are effectively secluded from pre-formed antibody. Once
transmission has occurred, cell–cell spread again takes
over; the window for effective neutralization is shut.
Fusion-complex conformation changes do not act alone in
antibodyevasion.Thehighlyimmunogenicgp150bothdrives
Fc receptor-dependent infection and, through its immuno-
dominance, suppresses the production of antibodies that
might otherwise neutralize (Gillet et al., 2007a). The gB N
terminus is protected by O-glycosylation and, in turn,
protects a key epitope on gH/gL (Gillet & Stevenson,
2007b). Such mechanisms complement that described here
by reducing the exposure of upstream forms of virion fusion
proteins to antibody. For MuHV-4 at least, much of the
complexity of herpesvirus entry makes sense as antibody
evasion.
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